Clinical Research Directory
Browse clinical research sites, groups, and studies.
4SCAR19U T Cells Targeting B Cell Malignancies
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.
Official title: Universal 4SCAR19U T Cell Therapy for the Treatment of Relapsed and Refractory B Cell Malignancies
Key Details
Gender
All
Age Range
6 Months - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-10-31
Completion Date
2026-12-31
Last Updated
2023-10-12
Healthy Volunteers
No
Conditions
Interventions
Universal CD19-specific CAR gene-engineered T cells
Infusion of 4SCAR19U cells
Locations (1)
Shenzhen Geno-Immune Medical Institute
Shenzhen, Guangdong, China